Vigabatrin + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine Dependence
Conditions
Cocaine Dependence
Trial Timeline
Apr 1, 2007 → Nov 1, 2007
NCT ID
NCT00527683About Vigabatrin + Placebo
Vigabatrin + Placebo is a phase 2 stage product being developed by Catalyst Pharmaceuticals for Cocaine Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00527683. Target conditions include Cocaine Dependence.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00611130 | Phase 2 | Completed |
| NCT00527683 | Phase 2 | Completed |
Competing Products
13 competing products in Cocaine Dependence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy | Johnson & Johnson | Phase 3 | 77 |
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| quetiapine fumarate + Matched Placebo | AstraZeneca | Pre-clinical | 23 |
| AFQ056 + Placebo | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| ALKS 33-BUP + ALKS 33 + Placebo | Alkermes | Phase 1 | 30 |
| VIVITROL (Naltrexone extended-release injectable suspension) + Placebo | Alkermes | Phase 2 | 49 |
| vigabatrin + placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2/3 | 60 |
| CPP-115 + Placebo | Catalyst Pharmaceuticals | Phase 1 | 28 |
| TNX-1300 | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-1300 (Injection) + Placebo (Injection) | Tonix Pharmaceuticals | Phase 2 | 44 |